

# Nassim Kamar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8105554/publications.pdf>

Version: 2024-02-01

309  
papers

18,515  
citations

13865

67  
h-index

16183

124  
g-index

323  
all docs

323  
docs citations

323  
times ranked

13141  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients. New England Journal of Medicine, 2008, 358, 811-817.   | 27.0 | 1,197     |
| 2  | Hepatitis E. Lancet, The, 2012, 379, 2477-2488.  | 13.7 | 805       |
| 3  | Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. New England Journal of Medicine, 2021, 385, 661-662.   | 27.0 | 728       |
| 4  | Insertions and Duplications in the Polyproline Region of the Hepatitis E Virus. Frontiers in Microbiology, 2020, 11, 1.  | 3.5  | 599       |
| 5  | Factors Associated With Chronic Hepatitis in Patients With Hepatitis E Virus Infection Who Have Received Solid Organ Transplants. Gastroenterology, 2011, 140, 1481-1489.            | 1.3  | 570       |
| 6  | Hepatitis E Virus Infection. Clinical Microbiology Reviews, 2014, 27, 116-138.   | 13.6 | 512       |
| 7  | Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients. New England Journal of Medicine, 2014, 370, 1111-1120.   | 27.0 | 436       |
| 8  | EASL Clinical Practice Guidelines on hepatitis E virus infection. Journal of Hepatology, 2018, 68, 1256-1271.  | 3.7  | 425       |
| 9  | Hepatitis E virus infection. Nature Reviews Disease Primers, 2017, 3, 17086.   | 30.5 | 386       |
| 10 | Hepatitis E Virus Antibodies in Blood Donors, France. Emerging Infectious Diseases, 2011, 17, 2309-2312.   | 4.3  | 314       |
| 11 | Each additional hour of cold ischemia time significantly increases the risk of graft failure and mortality following renal transplantation. Kidney International, 2015, 87, 343-349. | 5.2  | 287       |
| 12 | Hepatitis E Virus and Neurologic Disorders. Emerging Infectious Diseases, 2011, 17, 173-179.   | 4.3  | 279       |
| 13 | Ribavirin Therapy Inhibits Viral Replication on Patients With Chronic Hepatitis E Virus Infection. Gastroenterology, 2010, 139, 1612-1618.   | 1.3  | 265       |
| 14 | Hepatitis E Virus Strains in Rabbits and Evidence of a Closely Related Strain in Humans, France. Emerging Infectious Diseases, 2012, 18, 1274-81.                                    | 4.3  | 221       |
| 15 | Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients. Transplantation, 2017, 101, S1-S56.                                | 1.0  | 217       |
| 16 | An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. Kidney International, 2020, 98, 1549-1558.         | 5.2  | 213       |
| 17 | Influence of Immunosuppressive Therapy on the Natural History of Genotype 3 Hepatitis-E Virus Infection After Organ Transplantation. Transplantation, 2010, 89, 353-360.             | 1.0  | 201       |
| 18 | Hepatitis E virus and neurological injury. Nature Reviews Neurology, 2016, 12, 77-85.  | 10.1 | 198       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Rituximab Therapy for Acute Humoral Rejection After Kidney Transplantation. Transplantation, 2007, 83, 1277-1280.  | 1.0 | 194       |
| 20 | Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ: British Medical Journal, 2019, 366, l4923.  | 2.3 | 191       |
| 21 | Is COVID-19 infection more severe in kidney transplant recipients?. American Journal of Transplantation, 2021, 21, 1295-1303.  | 4.7 | 190       |
| 22 | Pegylated Interferon- $\alpha$ for Treating Chronic Hepatitis E Virus Infection after Liver Transplantation. Clinical Infectious Diseases, 2010, 50, e30-e33.  | 5.8 | 180       |
| 23 | <i>Nocardia</i> Infection in Solid Organ Transplant Recipients: A Multicenter European Case-control Study. Clinical Infectious Diseases, 2016, 63, 338-345.  | 5.8 | 179       |
| 24 | Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transplantation, 2010, 16, 74-82.  | 2.4 | 176       |
| 25 | Characteristics of Autochthonous Hepatitis E Virus Infection in Solid-Organ Transplant Recipients in France. Journal of Infectious Diseases, 2010, 202, 835-844.   | 4.0 | 174       |
| 26 | Evidence that Clearance of Hepatitis C Virus RNA after $\alpha$ -Interferon Therapy in Dialysis Patients Is Sustained after Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2003, 14, 2092-2098. | 6.1 | 173       |
| 27 | Hepatitis E Virus and the Kidney in Solid-Organ Transplant Patients. Transplantation, 2012, 93, 617-623.   | 1.0 | 170       |
| 28 | Development and Validation of a Modified Full Age Spectrum Creatinine-Based Equation to Estimate Glomerular Filtration Rate. Annals of Internal Medicine, 2021, 174, 183-191.  | 3.9 | 157       |
| 29 | Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies. Transplantation, 2010, 90, 1528-1535.                              | 1.0 | 156       |
| 30 | Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. BMJ, The, 2015, 351, h3557.   | 6.0 | 146       |
| 31 | Hepatitis E Virus Genotype 3 Diversity, France. Emerging Infectious Diseases, 2009, 15, 110-114.   | 4.3 | 141       |
| 32 | Rabbit Hepatitis E Virus Infections in Humans, France. Emerging Infectious Diseases, 2017, 23, 1191-1193.  | 4.3 | 139       |
| 33 | Hepatitis E Virus Re-infections in Solid-Organ-Transplant Recipients Can Evolve Into Chronic Infections. Journal of Infectious Diseases, 2014, 209, 1900-1906.   | 4.0 | 136       |
| 34 | Hepatitis E Virus Infection without Reactivation in Solid-Organ Transplant Recipients, France. Emerging Infectious Diseases, 2011, 17, 30-37.  | 4.3 | 134       |
| 35 | Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants. Annals of Internal Medicine, 2021, 174, 1336-1338.   | 3.9 | 122       |
| 36 | Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. American Journal of Transplantation, 2022, 22, 322-323.  | 4.7 | 120       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Natural History of Hepatitis C Virus-Related Liver Fibrosis After Renal Transplantation. American Journal of Transplantation, 2005, 5, 1704-1712.   | 4.7 | 119       |
| 38 | Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation. Clinical Gastroenterology and Hepatology, 2015, 13, 1993-2001.e2.                    | 4.4 | 118       |
| 39 | Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept. Transplantation, 2021, 105, e94-e95.                          | 1.0 | 105       |
| 40 | Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant. JAMA Network Open, 2021, 4, e2136030.  | 5.9 | 103       |
| 41 | Occurrence of severe COVID-19 in vaccinated transplant patients. Kidney International, 2021, 100, 477-479.  | 5.2 | 101       |
| 42 | Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients. Journal of Clinical Virology, 2013, 58, 624-628.   | 3.1 | 98        |
| 43 | Extrahepatic manifestations of hepatitis E virus. Liver International, 2016, 36, 467-472.   | 3.9 | 98        |
| 44 | Hepatitis E Virus Quasispecies and the Outcome of Acute Hepatitis E in Solid-Organ Transplant Patients. Journal of Virology, 2012, 86, 10006-10014.   | 3.4 | 97        |
| 45 | Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. Clinical Infectious Diseases, 2022, 75, 690-701.          | 5.8 | 97        |
| 46 | Hepatitis E Virus Infects Neurons and Brains. Journal of Infectious Diseases, 2017, 215, 1197-1206.   | 4.0 | 94        |
| 47 | Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment. Journal of the American Society of Nephrology: JASN, 2018, 29, 620-635. | 6.1 | 94        |
| 48 | Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. Nephrology Dialysis Transplantation, 2010, 25, 2792-2795.                             | 0.7 | 92        |
| 49 | High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrology Dialysis Transplantation, 2021, 36, 1704-1709.   | 0.7 | 87        |
| 50 | Diabetes mellitus after kidney transplantation: a French multicentre observational study. Nephrology Dialysis Transplantation, 2007, 22, 1986-1993.   | 0.7 | 85        |
| 51 | IMPact of the COVID-19 epidemic on the moRTality of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT). Kidney International, 2020, 98, 1568-1577.               | 5.2 | 85        |
| 52 | Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. American Journal of Kidney Diseases, 2003, 42, 184-192.                 | 1.9 | 83        |
| 53 | Hepatitis E Virus Infection in Immunosuppressed Patients: Natural History and Therapy. Seminars in Liver Disease, 2013, 33, 062-070.  | 3.6 | 82        |
| 54 | Good Performance of Immunoglobulin M Assays in Diagnosing Genotype 3 Hepatitis E Virus Infections. Vaccine Journal, 2009, 16, 772-774.  | 3.1 | 80        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Hepatitis E virus infection and acute non-traumatic neurological injury: A prospective multicentre study. <i>Journal of Hepatology</i> , 2017, 67, 925-932.   | 3.7 | 80        |
| 56 | Hepatitis E virus: Chronic infection, extra-hepatic manifestations, and treatment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 20-27.  | 1.5 | 78        |
| 57 | Donor-Specific Antibodies after Ceasing Immunosuppressive Therapy, with or without an Allograft Nephrectomy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1310-1319.                       | 4.5 | 77        |
| 58 | Hepatitis E Pathogenesis. <i>Viruses</i> , 2016, 8, 212.  | 3.3 | 77        |
| 59 | Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. <i>American Journal of Kidney Diseases</i> , 2004, 43, 140-146.  | 1.9 | 76        |
| 60 | Rituximab Therapy for De Novo Mixed Cryoglobulinemia in Renal Transplant Patients. <i>Transplantation</i> , 2005, 80, 1560-1564.  | 1.0 | 76        |
| 61 | Incidence of HCV infection in French hemodialysis units: A prospective study. <i>Journal of Medical Virology</i> , 2005, 77, 70-76.   | 5.0 | 75        |
| 62 | Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy. <i>Neurology</i> , 2017, 89, 909-917.  | 1.1 | 75        |
| 63 | Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results. <i>Journal of Clinical Oncology</i> , 2018, 36, 2612-2620.   | 1.6 | 74        |
| 64 | Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 1204-1211.   | 5.8 | 74        |
| 65 | Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections. <i>Journal of Clinical Medicine</i> , 2020, 9, 331.  | 2.4 | 73        |
| 66 | Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence – The ANRS CUPILT study. <i>Journal of Hepatology</i> , 2016, 65, 711-718.  | 3.7 | 72        |
| 67 | Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. <i>Kidney International</i> , 2018, 94, 663-673.   | 5.2 | 72        |
| 68 | De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients. <i>Transplant International</i> , 2015, 28, 1371-1382.  | 1.6 | 70        |
| 69 | An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. <i>Kidney International</i> , 2019, 96, 231-244. | 5.2 | 69        |
| 70 | Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 734-740.                               | 2.4 | 68        |
| 71 | Chronic Hepatitis E Virus Infection: Successful Virologic Response to Pegylated Interferon- $\alpha$ Therapy. <i>Annals of Internal Medicine</i> , 2010, 153, 135.  | 3.9 | 66        |
| 72 | Entecavir Therapy for Adefovir-Resistant Hepatitis B Virus Infection in Kidney and Liver Allograft Recipients. <i>Transplantation</i> , 2008, 86, 611-614.  | 1.0 | 65        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 73 | RIC $\alpha$ 1 is a key antiviral interferon $\alpha$ -stimulated gene against hepatitis E virus regardless of interferon production. Hepatology, 2017, 65, 1823-1839.  | 7.3  | 63        |
| 74 | Liver histology in patients with sporadic acute hepatitis E: a study of 11 patients from South-West France. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 405-410. | 2.8  | 62        |
| 75 | Protracted Fecal Shedding of HEV During Ribavirin Therapy Predicts Treatment Relapse. Clinical Infectious Diseases, 2015, 60, 96-99.  | 5.8  | 62        |
| 76 | Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy. Antimicrobial Agents and Chemotherapy, 2016, 60, 1608-1614.  | 3.2  | 62        |
| 77 | Treatment of Hepatitis C Virus Infection (HCV) After Renal Transplantation: Implications for HCV-Positive Dialysis Patients Awaiting a Kidney Transplant. Transplantation, 2006, 82, 853-856.                         | 1.0  | 61        |
| 78 | Treatment of autochthonous acute hepatitis E with short-term ribavirin: a multicenter retrospective study. Liver International, 2016, 36, 328-333.  | 3.9  | 61        |
| 79 | Validation of Immunological Biomarkers for the Pharmacodynamic Monitoring of Immunosuppressive Drugs in Humans. Therapeutic Drug Monitoring, 2007, 29, 77-86.   | 2.0  | 60        |
| 80 | Chronic Hepatitis E Virus Infection and Treatment. Journal of Clinical and Experimental Hepatology, 2013, 3, 134-140.   | 0.9  | 60        |
| 81 | An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients. Transplantation, 2015, 99, 2124-2131.  | 1.0  | 60        |
| 82 | mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?. Journal of Nephrology, 2010, 23, 133-42.  | 2.0  | 59        |
| 83 | Hepatitis E virus-induced severe myositis. Journal of Hepatology, 2012, 57, 1152-1153.  | 3.7  | 58        |
| 84 | Characterization of the Polyproline Region of the Hepatitis E Virus in Immunocompromised Patients. Journal of Virology, 2014, 88, 12017-12025.  | 3.4  | 58        |
| 85 | Hepatitis E Virus $\alpha$ -Induced Cryoglobulinemic Glomerulonephritis in a Nonimmunocompromised Person. American Journal of Kidney Diseases, 2016, 67, 660-663.   | 1.9  | 58        |
| 86 | Hepatitis E virus replication in human intestinal cells. Gut, 2020, 69, 901-910.  | 12.1 | 58        |
| 87 | Low risk of hepatitis E virus reactivation after haematopoietic stem cell transplantation. Journal of Clinical Virology, 2012, 54, 152-155.   | 3.1  | 56        |
| 88 | Acute hepatitis and renal function impairment related to infection by hepatitis E virus in a renal allograft recipient. American Journal of Kidney Diseases, 2005, 45, 193-196.                                       | 1.9  | 55        |
| 89 | No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transplant International, 2010, 23, 594-601.                                   | 1.6  | 54        |
| 90 | Pneumocystis Pneumonia in Solid-Organ Transplant Recipients. Journal of Fungi (Basel, Switzerland), 2015, 1, 293-331.   | 3.5  | 54        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2309-2316.   | 0.7 | 53        |
| 92  | Influence of Polyproline Region and Macro Domain Genetic Heterogeneity on HEV Persistence in Immunocompromised Patients. <i>Journal of Infectious Diseases</i> , 2014, 209, 300-303.  | 4.0 | 53        |
| 93  | Negative Impact of One-Year Anemia on Long-Term Patient and Graft Survival in Kidney Transplant Patients Receiving Calcineurin Inhibitors and Mycophenolate Mofetil. <i>Transplantation</i> , 2008, 85, 1120-1124.                            | 1.0 | 51        |
| 94  | Sofosbuvir and Daclatasvir Anti-“Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient. <i>Gastroenterology</i> , 2017, 152, 300-301.                                     | 1.3 | 51        |
| 95  | Acute hepatitis E in French patients and neurological manifestations. <i>Journal of Infection</i> , 2018, 77, 220-226.  | 3.3 | 51        |
| 96  | Assessing Renal Function With Daclizumab Induction and Delayed Tacrolimus Introduction in Liver Transplant Recipients. <i>Transplantation</i> , 2010, 89, 1504-1510.  | 1.0 | 50        |
| 97  | Hepatitis E in developed countries: current status and future perspectives. <i>Future Microbiology</i> , 2014, 9, 1361-1372.  | 2.0 | 49        |
| 98  | Transfusion-Transmitted Hepatitis E Virus Infection in France. <i>Transfusion Medicine Reviews</i> , 2019, 33, 146-153.   | 2.0 | 49        |
| 99  | Performance of Two Commercial Assays for Detecting Hepatitis E Virus RNA in Acute or Chronic Infections. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1913-1916.   | 3.9 | 48        |
| 100 | Predictive Factors for Posttransplant Diabetes Mellitus Within One-Year of Liver Transplantation. <i>Transplantation</i> , 2008, 85, 1436-1442.   | 1.0 | 47        |
| 101 | Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study. <i>Transplant International</i> , 2012, 25, 1059-1064. | 1.6 | 47        |
| 102 | Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw348.  | 0.7 | 46        |
| 103 | Hepatitis E virus infections in Europe. <i>Journal of Clinical Virology</i> , 2019, 120, 20-26.   | 3.1 | 46        |
| 104 | Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen. <i>Clinical Transplantation</i> , 2013, 27, 455-462.                                     | 1.6 | 45        |
| 105 | Performance of an antigen assay for diagnosing acute hepatitis E virus genotype 3 infection. <i>Journal of Clinical Virology</i> , 2016, 79, 1-5.   | 3.1 | 44        |
| 106 | Donor-specific antibodies and liver transplantation. <i>Human Immunology</i> , 2016, 77, 1063-1070.   | 2.4 | 44        |
| 107 | Definitive Clearance of a Chronic Hepatitis E Virus Infection With Ribavirin Treatment. <i>American Journal of Gastroenterology</i> , 2011, 106, 1562-1563.   | 0.4 | 43        |
| 108 | Acute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a031872.   | 6.2 | 43        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 109 | Antibiotics versus no therapy in kidney transplant recipients with asymptomatic bacteriuria (BiRT): a pragmatic, multicentre, randomized, controlled trial. <i>Clinical Microbiology and Infection</i> , 2021, 27, 398-405.                 | 6.0  | 43        |
| 110 | Characterization of the Specificity, Functionality, and Durability of Host Tâ€Cell Responses Against the Fullâ€Length Hepatitis E Virus. <i>Hepatology</i> , 2016, 64, 1934-1950.   | 7.3  | 42        |
| 111 | Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies. <i>Emerging Infectious Diseases</i> , 2015, 21, 1466-1469.   | 4.3  | 41        |
| 112 | Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation. <i>World Journal of Gastroenterology</i> , 2009, 15, 3426.   | 3.3  | 41        |
| 113 | Trajectories of glomerular filtration rate and progression to end stage kidney disease afterÂkidney transplantation. <i>Kidney International</i> , 2021, 99, 186-197.   | 5.2  | 40        |
| 114 | Amantadine therapy in renal transplant patients with hepatitis C virus infection. <i>Journal of Clinical Virology</i> , 2004, 30, 110-114.  | 3.1  | 39        |
| 115 | CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality. <i>Transplant International</i> , 2014, 27, 956-965.                                   | 1.6  | 38        |
| 116 | Acute rejection after antiâ€SARS-CoV-2 mRNA vaccination in a patient who underwent a kidney transplant. <i>Kidney International</i> , 2021, 100, 238-239.   | 5.2  | 38        |
| 117 | Anti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patients. <i>American Journal of Transplantation</i> , 2022, 22, 1467-1474. | 4.7  | 37        |
| 118 | Chronic hepatitis E: Advancing research and patient care. <i>Journal of Hepatology</i> , 2022, 77, 1109-1123.   | 3.7  | 37        |
| 119 | Hepatitis E virus infection. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 271-278.  | 2.3  | 36        |
| 120 | Treatment of HEV Infection in Patients with a Solid-Organ Transplant and Chronic Hepatitis. <i>Viruses</i> , 2016, 8, 222.  | 3.3  | 36        |
| 121 | Predictive Factors of Anemia within the First Year Post Renal Transplant. <i>Transplantation</i> , 2005, 80, 903-909.   | 1.0  | 34        |
| 122 | Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 1043-1047.                               | 0.7  | 34        |
| 123 | Adherence profiles in kidney transplant patients: Causes and consequences. <i>Patient Education and Counseling</i> , 2020, 103, 189-198.  | 2.2  | 34        |
| 124 | Predictive Factors for Chronic Renal Failure One Year after Orthotopic Liver Transplantation. <i>Renal Failure</i> , 2006, 28, 419-425.   | 2.1  | 33        |
| 125 | Ribavirin for Chronic Hepatitis E Virus Infection. <i>New England Journal of Medicine</i> , 2014, 370, 2446-2448.   | 27.0 | 33        |
| 126 | Temporal evolution of the distribution of hepatitis E virus genotypes in Southwestern France. <i>Infection, Genetics and Evolution</i> , 2015, 35, 50-55.   | 2.3  | 33        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Diversity of hepatitis E virus genotype 3. Reviews in Medical Virology, 2018, 28, e1987.  | 8.3 | 33        |
| 128 | Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation. Liver Transplantation, 2016, 22, 1367-1378.   | 2.4 | 32        |
| 129 | Treatment of hepatitis E virus. Current Opinion in Infectious Diseases, 2016, 29, 639-644.  | 3.1 | 31        |
| 130 | Impact of estimation versus direct measurement of predonation glomerular filtration rate on the eligibility of potential living kidney donors. Kidney International, 2019, 95, 896-904.                                   | 5.2 | 31        |
| 131 | Hepatitis E virus genotype 3 and capsid protein in the blood and urine of immunocompromised patients. Journal of Infection, 2019, 78, 232-240.  | 3.3 | 31        |
| 132 | Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation. Transplantation, 2016, 100, 640-647.   | 1.0 | 29        |
| 133 | Hepatitis E virus-associated cryoglobulinemia in solid organ transplant recipients. Liver International, 2018, 38, 2178-2189.   | 3.9 | 29        |
| 134 | Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis. Transplant International, 2009, 22, 568-573.                       | 1.6 | 28        |
| 135 | The age-calibrated measured glomerular filtration rate improves living kidney donation selection process. Kidney International, 2018, 94, 616-624.  | 5.2 | 28        |
| 136 | Pregnancy after kidney transplantation: outcome and anti-human leucocyte antigen alloimmunization risk. Nephrology Dialysis Transplantation, 2014, 29, 1786-1793.   | 0.7 | 26        |
| 137 | Quantification of HEV RNA by Droplet Digital PCR. Viruses, 2016, 8, 233.  | 3.3 | 26        |
| 138 | Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years. Liver Transplantation, 2019, 25, 1822-1832.  | 2.4 | 26        |
| 139 | Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients. Journal of Hepatology, 2019, 70, 206-209.   | 3.7 | 26        |
| 140 | Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation?. American Journal of Transplantation, 2021, 21, 1641-1649.    | 4.7 | 26        |
| 141 | Poor Long-Term Outcome in Second Kidney Transplantation: A Delayed Event. PLoS ONE, 2012, 7, e47915.  | 2.5 | 25        |
| 142 | Conventional and innate lymphocytes response at the acute phase of HEV infection in transplanted patients. Journal of Infection, 2016, 72, 723-730.   | 3.3 | 25        |
| 143 | Hepatitis E Virus Infection in Solid Organ Transplant Recipients, France. Emerging Infectious Diseases, 2017, 23, 353-356.  | 4.3 | 25        |
| 144 | Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study. Advances in Therapy, 2019, 36, 462-477. | 2.9 | 25        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 145 | Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study. <i>The Lancet Digital Health</i> , 2021, 3, e795-e805.      | 12.3 | 25        |
| 146 | Early Administration of Anti-SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients. <i>Kidney International Reports</i> , 2022, 7, 1241-1247.  | 0.8  | 25        |
| 147 | Predictive Factors for Humoral Response After 2-dose SARS-CoV-2 Vaccine in Solid Organ Transplant Patients. <i>Transplantation Direct</i> , 2022, 8, e1248.  | 1.6  | 25        |
| 148 | Pharmacodynamic Evaluation of the First Dose of Mycophenolate Mofetil Before Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 936-942.  | 4.5  | 24        |
| 149 | Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy. <i>Emerging Infectious Diseases</i> , 2019, 25, 2145-2147.   | 4.3  | 24        |
| 150 | Anti-SARS-CoV-2 Monoclonal Antibodies in Solid-organ Transplant Patients. <i>Transplantation</i> , 2021, 105, e146-e147.   | 1.0  | 24        |
| 151 | Performance of creatinine-based equations to estimate glomerular filtration rate with a methodology adapted to the context of drug dosage adjustment. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2118-2127.             | 2.4  | 24        |
| 152 | Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney transplant patients. <i>Journal of Medical Virology</i> , 2008, 80, 1012-1017.  | 5.0  | 23        |
| 153 | Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3720-3726.   | 0.7  | 23        |
| 154 | Impact of post-transplant anemia on patient and graft survival rates after kidney transplantation: a meta-analysis. <i>Clinical Transplantation</i> , 2012, 26, 461-469.   | 1.6  | 23        |
| 155 | Screening, diagnosis and risks associated with Hepatitis E virus infection. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 403-418.  | 4.4  | 23        |
| 156 | Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 829-838.                   | 6.1  | 23        |
| 157 | Factors Associated With COVID-19 Vaccine Response in Transplant Recipients: A Systematic Review and Meta-analysis. <i>Transplantation</i> , 2022, 106, 2068-2075.  | 1.0  | 23        |
| 158 | New-Onset Diabetes and Nephropathy after Renal Transplantation. <i>Contributions To Nephrology</i> , 2011, 170, 247-255.   | 1.1  | 22        |
| 159 | Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation. <i>Transplant International</i> , 2015, 28, 255-258.                          | 1.6  | 22        |
| 160 | Preemptive second kidney transplantation is associated with better graft survival compared with non-preemptive second transplantation: a multicenter French 2000-2014 cohort study. <i>Transplant International</i> , 2018, 31, 408-423. | 1.6  | 22        |
| 161 | Cytokines correlate with age in healthy volunteers, dialysis patients and kidney-transplant patients. <i>Cytokine</i> , 2009, 45, 169-173.   | 3.2  | 21        |
| 162 | Inhibition of T-cell activation and proliferation by mycophenolic acid in patients awaiting liver transplantation: PK/PD relationships. <i>Pharmacological Research</i> , 2011, 63, 432-438.   | 7.1  | 21        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia. <i>Transplant International</i> , 2016, 29, 315-322.   | 1.6 | 21        |
| 164 | Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19. <i>Annals of Internal Medicine</i> , 2020, 173, 501-503.  | 3.9 | 21        |
| 165 | Rituximab for Humoral Rejection After Kidney Transplantation: An Update. <i>Transplantation</i> , 2009, 87, 1261.   | 1.0 | 20        |
| 166 | Does HEV subtype play a role in the severity of acute hepatitis E?. <i>Liver International</i> , 2020, 40, 333-337.   | 3.9 | 20        |
| 167 | Identification of Predictive Markers and Outcomes of Late-onset <i>Pneumocystis jirovecii</i> Pneumonia in Kidney Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2021, 73, e1456-e1463.                                       | 5.8 | 20        |
| 168 | Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C. <i>Clinical Transplantation</i> , 2005, 19, 83-89.  | 1.6 | 19        |
| 169 | Pre-emptive intravenous ganciclovir versus valganciclovir prophylaxis for de novo cytomegalovirus-seropositive kidney-transplant recipients. <i>Transplant International</i> , 2010, 23, 1056-1064.   | 1.6 | 19        |
| 170 | Belatacept in recurrent focal segmental glomerulosclerosis after kidney transplantation. <i>Transplant International</i> , 2015, 28, 1109-1110.   | 1.6 | 19        |
| 171 | Performance of a new rapid test for detecting anti-hepatitis E virus immunoglobulin M in immunocompetent and immunocompromised patients. <i>Journal of Clinical Virology</i> , 2015, 70, 101-104.   | 3.1 | 19        |
| 172 | A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients. <i>Clinical Nephrology</i> , 2012, 77, 126-136. | 0.7 | 19        |
| 173 | Interference of therapeutic antibodies used in desensitization protocols on lymphocytotoxicity crossmatch results. <i>Transplant Immunology</i> , 2015, 32, 151-155.  | 1.2 | 18        |
| 174 | Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective. <i>Kidney International</i> , 2018, 94, 206-213.  | 5.2 | 18        |
| 175 | Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation. <i>Journal of Hepatology</i> , 2019, 70, 831-838.  | 3.7 | 18        |
| 176 | An extension of the RITUXERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody-mediated rejection after renal transplantation. <i>Transplant International</i> , 2020, 33, 786-795.            | 1.6 | 18        |
| 177 | Hepatitis C virus and kidney disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 328-333.   | 1.5 | 17        |
| 178 | Does chronic hepatitis E virus infection exist in immunocompetent patients?. <i>Hepatology</i> , 2014, 60, 427-427.   | 7.3 | 17        |
| 179 | Influence of Anemia on Patient and Graft Survival After Renal Transplantation. <i>Transplantation</i> , 2014, 97, 168-175.  | 1.0 | 17        |
| 180 | Outcome of Liver Transplant Patients With Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies. <i>Liver Transplantation</i> , 2020, 26, 256-267.   | 2.4 | 17        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 181 | Polyoma BK virus-associated nephropathy in kidney-transplant patients: Effects of leflunomide on T-cell functions and disease outcome. <i>International Immunopharmacology</i> , 2009, 9, 1131-1136.   | 3.8 | 16        |
| 182 | Impact of very early high doses of recombinant erythropoietin on anemia and allograft function in de novo kidney-transplant patients. <i>Transplant International</i> , 2010, 23, 277-284.   | 1.6 | 16        |
| 183 | Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab. <i>Clinical Immunology</i> , 2017, 183, 1-7.  | 3.2 | 16        |
| 184 | Dosing ribavirin in hepatitis E-infected solid organ transplant recipients. <i>Pharmacological Research</i> , 2018, 130, 308-315.  | 7.1 | 16        |
| 185 | Effector memory CD8 T cell response elicits Hepatitis E Virus genotype 3 pathogenesis in the elderly. <i>PLoS Pathogens</i> , 2021, 17, e1009367.  | 4.7 | 16        |
| 186 | Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations. <i>Lancet Microbe</i> , 2022, 3, e325-e326.   | 7.3 | 16        |
| 187 | Incidence, predictors and prognosis of genotype 4 hepatitis E related liver failure: A tertiary nested case-control study. <i>Liver International</i> , 2019, 39, 2291-2300.   | 3.9 | 15        |
| 188 | Evaluation of the efficacy and safety of a slow conversion from calcineurin inhibitor- to sirolimus-based therapies in maintenance renal-transplant patients presenting with moderate renal insufficiency. <i>Transplant International</i> , 2007, 20, 128-34. | 1.6 | 14        |
| 189 | Kidney histology and function in liver transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2355-2361.  | 0.7 | 14        |
| 190 | Hepatitis E in Transplantation. <i>Current Infectious Disease Reports</i> , 2016, 18, 8.   | 3.0 | 14        |
| 191 | Transfusion-acquired hepatitis E infection misdiagnosed as severe critical illness polyneuromyopathy in a heart transplant patient. <i>Transplant Infectious Disease</i> , 2017, 19, e12784.   | 1.7 | 14        |
| 192 | No Clear Evidence for an Effect of Sofosbuvir Against Hepatitis E Virus in Organ Transplant Patients. <i>Hepatology</i> , 2019, 69, 1846-1847.   | 7.3 | 14        |
| 193 | Cytomegalovirus prophylaxis with valganciclovir in cytomegalovirus-seropositive kidney-transplant patients. <i>Journal of Medical Virology</i> , 2008, 80, 1228-1232.  | 5.0 | 13        |
| 194 | Occult Hepatitis C Virus Infection in Hemodialysis Patients: Examining the Evidence. <i>American Journal of Kidney Diseases</i> , 2009, 54, 10-12.   | 1.9 | 13        |
| 195 | A 3-month course of ciprofloxacin does not prevent BK virus replication in heavily immunosuppressed kidney-transplant patients. <i>Journal of Clinical Virology</i> , 2016, 79, 61-67.   | 3.1 | 13        |
| 196 | Histological long-term outcomes from acute antibody-mediated rejection following ABO-compatible liver transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 887-893.  | 2.8 | 13        |
| 197 | Dynamic predictions of long-term kidney graft failure: an information tool promoting patient-centred care. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1961-1969.   | 0.7 | 13        |
| 198 | Hepatitis E Virus: How It Escapes Host Innate Immunity. <i>Vaccines</i> , 2020, 8, 422.  | 4.4 | 13        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 199 | Successful Retransplantation of a Kidney Allograft Affected by Thrombotic Microangiopathy Into a Second Transplant Recipient. <i>American Journal of Kidney Diseases</i> , 2008, 52, 591-594.   | 1.9 | 12        |
| 200 | Alveolar and Blood T Lymphocyte Profiles in Pneumocystis jirovecii-Positive Patients: Effects of HIV Status. <i>Journal of Infectious Diseases</i> , 2011, 204, 544-553.  | 4.0 | 12        |
| 201 | Safety of renal transplantation in patients with bipolar or psychotic disorders: a retrospective study. <i>Transplant International</i> , 2018, 31, 377-385.  | 1.6 | 12        |
| 202 | Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. <i>Transplantation Reviews</i> , 2019, 33, 191-199.                      | 2.9 | 12        |
| 203 | Seroprevalence of hepatitis E virus (HEV) in a general adult population in Northern Norway: the TromsÅ study. <i>Medical Microbiology and Immunology</i> , 2019, 208, 715-725.  | 4.8 | 12        |
| 204 | Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation. <i>Transplant International</i> , 2015, 28, 928-937.  | 1.6 | 11        |
| 205 | Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients. <i>Transplant International</i> , 2016, 29, 1257-1265.  | 1.6 | 11        |
| 206 | Direct-acting antiviral therapy for hepatitis E virus?. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 154-155.   | 8.1 | 11        |
| 207 | Predictive model of 1-year postoperative renal function after living donor nephrectomy. <i>International Urology and Nephrology</i> , 2017, 49, 793-801.  | 1.4 | 11        |
| 208 | Detection of viral hepatitis E in clinical liver biopsies. <i>Histopathology</i> , 2017, 71, 580-590.   | 2.9 | 11        |
| 209 | 12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation. <i>Hepatology</i> , 2018, 68, 1277-1287.   | 7.3 | 11        |
| 210 | Prospects for improved glomerular filtration rate estimation based on creatinine results from a transnational multicentre study. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 674-683.   | 2.9 | 11        |
| 211 | Temporal trends in living kidney donation in France between 2007 and 2017. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 730-738.  | 0.7 | 11        |
| 212 | Hepatitis C virus infection in nephrology patients. <i>Journal of Nephropathology</i> , 2013, 2, 217-33.  | 0.2 | 11        |
| 213 | Impact of donor BK polyomavirus replication on recipient infections in living donor transplantation. <i>Transplant Infectious Disease</i> , 2018, 20, e12917.   | 1.7 | 10        |
| 214 | Outcomes of kidney transplant recipients admitted to the intensive care unit: a retrospective study of 200 patients. <i>BMC Anesthesiology</i> , 2019, 19, 130.   | 1.8 | 10        |
| 215 | A prospective study in male recipients of kidney transplantation reveals divergent patterns for inhibin B and testosterone secretions. <i>Basic and Clinical Andrology</i> , 2014, 24, 11.  | 1.9 | 9         |
| 216 | Comparison of graft and patient survival according to the transplantation centre policy for 1-year screening biopsy among stable kidney recipients: a propensity score-based study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 703-711. | 0.7 | 9         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 217 | Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin. <i>Viruses</i> , 2019, 11, 630.   | 3.3 | 9         |
| 218 | Failure to respond to ribavirin despite elevated intraerythrocyte zinc level in transplant patients with chronic hepatitis E virus infection. <i>Transplant Infectious Disease</i> , 2019, 21, e13050.                  | 1.7 | 9         |
| 219 | Outcomes of solid organ transplant recipients with invasive aspergillosis and other mold infections. <i>Transplant Infectious Disease</i> , 2020, 22, e13200.   | 1.7 | 9         |
| 220 | Niclosamide inhibits hepatitis E virus through suppression of NF-kappaB signalling. <i>Antiviral Research</i> , 2022, 197, 105228.  | 4.1 | 9         |
| 221 | Hepatitis E virus-specific T-cell response after transplantation. <i>Hepatology</i> , 2012, 55, 1643-1643.  | 7.3 | 8         |
| 222 | Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate. <i>Case Reports in Transplantation</i> , 2014, 2014, 1-4.  | 0.3 | 8         |
| 223 | Incidence of anti-HLA donor specific antibodies in liver-transplant patients given mTOR inhibitors without calcineurin inhibitors. <i>Journal of Hepatology</i> , 2014, 61, 963-965.                                    | 3.7 | 8         |
| 224 | Late isolated ocular toxoplasmosis in a belatacept-treated kidney transplant patient. <i>Transplant International</i> , 2016, 29, 1352-1353.  | 1.6 | 8         |
| 225 | Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation. <i>Case Reports in Transplantation</i> , 2017, 2017, 1-6.                          | 0.3 | 8         |
| 226 | Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study. <i>American Journal of Transplantation</i> , 2021, 21, 3021-3033.                   | 4.7 | 8         |
| 227 | Cytokine storm induced by a PD1 inhibitor in a renal transplant patient. <i>American Journal of Transplantation</i> , 2021, 21, 2616-2618.  | 4.7 | 8         |
| 228 | Clinical Utility of Biochemical Markers for the Prediction of COVID-19-Related Mortality in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2021, 6, 2689-2693.                                     | 0.8 | 8         |
| 229 | Rat Hepatitis E Virus: Presence in Humans in South-Western France?. <i>Frontiers in Medicine</i> , 2021, 8, 726363.   | 2.6 | 8         |
| 230 | Hepatitis E Virus Quasispecies in Cerebrospinal Fluid with Neurological Manifestations. <i>Vaccines</i> , 2021, 9, 1205.  | 4.4 | 8         |
| 231 | Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine. <i>Vaccines</i> , 2022, 10, 354.   | 4.4 | 8         |
| 232 | Casirivimab-imdevimab to Prevent SARS-CoV-2 Infections in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2022, 106, e275-e276.   | 1.0 | 8         |
| 233 | Evolution of hepatitis C virus quasispecies in renal transplant patients with de novo glomerulonephritis. <i>Journal of Medical Virology</i> , 2003, 69, 482-488.   | 5.0 | 7         |
| 234 | Mycophenolic Acid 12-Hour Area Under the Curve in De Novo Liver Transplant Patients Given Mycophenolate Mofetil at Fixed Versus Concentration-Controlled Doses. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 451-456. | 2.0 | 7         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 235 | An Association between BK Virus Replication in Bone Marrow and Cytopenia in Kidney-Transplant Recipients. <i>Journal of Transplantation</i> , 2014, 2014, 1-9.   | 0.5 | 7         |
| 236 | Direct-acting antivirals and hepatitis B virus (<scp>HBV</scp>) reactivation in co-infected <scp>HBV</scp>/<scp>HCV</scp> kidney-transplant recipients. <i>Transplant Infectious Disease</i> , 2018, 20, e12864.       | 1.7 | 7         |
| 237 | Actinomycosis: An infrequent disease in renal transplant recipients?. <i>Transplant Infectious Disease</i> , 2018, 20, e12970.   | 1.7 | 7         |
| 238 | Kidney transplantation improves the clinical outcomes of Acute Intermittent Porphyria. <i>Molecular Genetics and Metabolism</i> , 2020, 131, 259-266.  | 1.1 | 7         |
| 239 | Specific organization for in-hospital belatacept infusion to avoid nosocomial transmission during the SARS-CoV-2 pandemic. <i>American Journal of Transplantation</i> , 2020, 20, 2962-2963.                           | 4.7 | 7         |
| 240 | Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection. <i>Journal of Viral Hepatitis</i> , 2021, 28, 431-435.  | 2.0 | 7         |
| 241 | Early post-transplant complications following ABO-incompatible kidney transplantation. <i>Journal of Nephropathology</i> , 2016, 5, 19-27.   | 0.2 | 7         |
| 242 | Treatment of Chronic Hepatitis C Virus Infection in Dialysis Patients: An Update. <i>Hepatitis Research and Treatment</i> , 2010, 2010, 1-6.   | 2.0 | 6         |
| 243 | Do kidney histology lesions predict long-term kidney function after liver transplantation?. <i>Clinical Transplantation</i> , 2012, 26, 927-934.   | 1.6 | 6         |
| 244 | Low- versus high-dose rituximab for antibody-mediated rejection after kidney transplantation. <i>Transplant International</i> , 2013, 26, e12-e14.   | 1.6 | 6         |
| 245 | Pretransplant urinary proteome analysis does not predict development of chronic kidney disease after liver transplantation. <i>Liver International</i> , 2015, 35, 1893-1901.  | 3.9 | 6         |
| 246 | Calcineurin Inhibitors Downregulate HNF-1 $\beta$ and May Affect the Outcome of HNF1B Patients After Renal Transplantation. <i>Transplantation</i> , 2016, 100, 1970-1978.   | 1.0 | 6         |
| 247 | Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 215-227.  | 3.1 | 6         |
| 248 | Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study. <i>American Journal of Transplantation</i> , 2017, 17, 2869-2878. | 4.7 | 6         |
| 249 | Performance of a commercial assay for detecting and quantifying HEV RNA in faeces. <i>Journal of Clinical Virology</i> , 2018, 109, 1-5.   | 3.1 | 6         |
| 250 | Combined Liver-Kidney Transplantation With Preformed Anti-human Leukocyte Antigen Donor-Specific Antibodies. <i>Kidney International Reports</i> , 2020, 5, 2202-2211.   | 0.8 | 6         |
| 251 | Cryptococcal Meningitis in Kidney Transplant Recipients: A Two-Decade Cohort Study in France. <i>Pathogens</i> , 2022, 11, 699.  | 2.8 | 6         |
| 252 | Hepatitis E virus infection in Iranian kidney-transplant patients. <i>Hepatitis Monthly</i> , 2011, 11, 927-928.   | 0.2 | 5         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 253 | Everolimus-induced recurrent pericardial effusion after kidney transplantation. Transplant International, 2013, 26, e36-e37.  | 1.6 | 5         |
| 254 | Isolated Aspergillosis Myocardial Abscesses in a Liver-Transplant Patient. Case Reports in Transplantation, 2014, 2014, 1-3.  | 0.3 | 5         |
| 255 | Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates. Journal of Transplantation, 2015, 2015, 1-5.   | 0.5 | 5         |
| 256 | Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients. Clinical Therapeutics, 2019, 41, 882-896.e3.   | 2.5 | 5         |
| 257 | Long-term, prolonged-release tacrolimus-based immunosuppression in de novo kidney transplant recipients: 5-year prospective follow-up of the ADHERE study patients. Transplant International, 2020, 33, 161-173.                | 1.6 | 5         |
| 258 | Epidemiological and clinical study of microsporidiosis in French kidney transplant recipients from 2005 to 2019: TRANSPORE registry. Transplant Infectious Disease, 2021, 23, e13708.   | 1.7 | 5         |
| 259 | Fatal encephalitis and Borna Disease Virus seropositivity in two kidney transplant patients living in the same nonendemic area. Transplant Infectious Disease, 2021, 23, .  | 1.7 | 5         |
| 260 | Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: A randomized, open-label, multicenter phase 4 trial. American Journal of Transplantation, 2022, 22, 1430-1441.     | 4.7 | 5         |
| 261 | Omicron breakthrough infection in a kidney transplant patient given pre-exposition casirivimab and imdevimab monoclonal antibodies. Transplant Infectious Disease, 2022, 24, .  | 1.7 | 5         |
| 262 | Successful pregnancy after ABO-incompatible kidney transplantation. Transplant International, 2016, 29, 506-507.  | 1.6 | 4         |
| 263 | Three-dimensional laparoscopy for living-donor nephrectomy with vaginal extraction: The first case. International Journal of Surgery Case Reports, 2017, 34, 87-89.   | 0.6 | 4         |
| 264 | Anti-CD2R blockers comparing with polyclonal antibodies: Higher risk of rejection without negative mid-term outcomes after ABO-incompatible kidney transplantation. Clinical Transplantation, 2019, 33, e13681.                 | 1.6 | 4         |
| 265 | Laparoscopy for living donor left nephrectomy: Comparison of three-dimensional and two-dimensional vision. Clinical Transplantation, 2019, 33, e13745.  | 1.6 | 4         |
| 266 | Should 12- or 24-week post-ribavirin follow-up be considered to define sustained virological response in transplant patients treated for chronic hepatitis E virus infection?. Transplant Infectious Disease, 2019, 21, e13065. | 1.7 | 4         |
| 267 | No evidence of occult hepatitis C or E virus infections in liver transplant patients with sustained virological response after therapy with direct acting agents. Transplant Infectious Disease, 2019, 21, e13093.              | 1.7 | 4         |
| 268 | Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients. Kidney International Reports, 2020, 5, 2195-2201.   | 0.8 | 4         |
| 269 | Cardiac impact of arteriovenous fistulas: what tools to assess?. Heart and Vessels, 2020, 35, 1583-1593.  | 1.2 | 4         |
| 270 | Kidney transplantation during the COVID-19 pandemic: Potential long-term consequences of an early post-transplant infection. Transplant Infectious Disease, 2021, 23, e13446.   | 1.7 | 4         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 271 | Comparison of two strategies based on mammalian target of rapamycin inhibitors in secondary prevention of non-melanoma skin cancer after kidney transplantation, a pilot study. <i>Clinical Transplantation</i> , 2021, 35, e14207.   | 1.6 | 4         |
| 272 | External Validation of a Predictive Model to Estimate Renal Function After Living Donor Nephrectomy. <i>Transplantation</i> , 2021, Publish Ahead of Print, 2445-2450.  | 1.0 | 4         |
| 273 | Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation. <i>Kidney International</i> , 2021, 100, 915-927.   | 5.2 | 4         |
| 274 | Impact of calcineurin inhibitor-free immunosuppression on de novo donor-specific antibody formation in liver transplant recipients. <i>Liver International</i> , 2022, 42, 1132-1143.   | 3.9 | 4         |
| 275 | Intrahepatic cytokine profile in renal-transplant patients infected by hepatitis C virus. <i>Journal of Medical Virology</i> , 2005, 76, 482-488.   | 5.0 | 3         |
| 276 | Malignancies in hepatitis C virus-positive and -negative kidney transplant recipients: A case-controlled study. <i>Transplant Infectious Disease</i> , 2017, 19, e12725.  | 1.7 | 3         |
| 277 | Impact of transplant accessibility for sensitized patients by avoiding unacceptable antigens. <i>Liver Transplantation</i> , 2017, 23, 880-886.   | 2.4 | 3         |
| 278 | The FcγRIIIA-158 VV genotype increased the risk of post-transplant lymphoproliferative disorder in T-cell-depleted kidney transplant recipients – a retrospective study. <i>Transplant International</i> , 2020, 33, 936-947.         | 1.6 | 3         |
| 279 | Living kidney donor evaluation for all candidates with normal estimated GFR for age. <i>Transplant International</i> , 2021, 34, 1123-1133.   | 1.6 | 3         |
| 280 | Microsporidiosis after liver transplantation: A French nationwide retrospective study. <i>Transplant Infectious Disease</i> , 2021, 23, e13665.   | 1.7 | 3         |
| 281 | Kidney Failure after Liver Transplantation. <i>Transplantation</i> , 2021, 2, 315-335.  | 0.6 | 3         |
| 282 | Response to the KDOQI US Commentary on the 2018 KDIGO Hepatitis C Guideline. <i>American Journal of Kidney Diseases</i> , 2021, 77, 152.  | 1.9 | 3         |
| 283 | Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference. <i>Journal of Hepatology</i> , 2019, 70, 1297-1300.   | 3.7 | 2         |
| 284 | Therapeutic education as a tool to improve patient-reported and clinical outcomes after renal transplantation: results of the EPHEGREN multicenter retrospective cohort study. <i>Transplant International</i> , 2021, 34, 2341-2352. | 1.6 | 2         |
| 285 | Hepatitis E Virus Infection in Iranian Kidney-Transplant Patients. <i>Hepatitis Monthly</i> , 2011, 11, 927-928.  | 0.2 | 2         |
| 286 | New evidence shows it is time to stop unnecessary use of antibiotics in kidney transplant recipients with asymptomatic bacteriuria. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 754-756.                                   | 0.7 | 2         |
| 287 | Spectrum of Kidney Disorders Associated with T-Cell Immunoclonal. <i>Journal of Clinical Medicine</i> , 2022, 11, 604.  | 2.4 | 2         |
| 288 | No evidence of genotype-3 hepatitis E virus-induced myocarditis. <i>Journal of Clinical Virology</i> , 2016, 76, 44.  | 3.1 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 289 | Should Persistent Hepatitis E Virus Replication in Transplant Patients Be Tolerated?. Transplantation, 2018, 102, e84-e85.  | 1.0 | 1         |
| 290 | Early necrotic skin lesions after a ABO-incompatible kidney transplantation: The threat ofCunninghamellaSpp.. Transplant Infectious Disease, 2019, 21, e13173.  | 1.7 | 1         |
| 291 | Possible patient to patient transmission of progressive multifocal leukoencephalopathy among kidney-transplant patients. Brazilian Journal of Infectious Diseases, 2020, 24, 473-474.   | 0.6 | 1         |
| 292 | A Randomized Prospective Study Comparing Anti-T-Lymphocyte Igs to Basiliximab in Highly Sensitized Kidney Transplant Patients. Kidney International Reports, 2020, 5, 1207-1217.  | 0.8 | 1         |
| 293 | Autoantibodies against granulocyte macrophage colony-stimulating factor and <i>Nocardia</i> infection in solid organ transplant recipients. Transplant International, 2020, 33, 1827-1829.                                    | 1.6 | 1         |
| 294 | Hepatitis E Infections in Transplants. , 2020, , 1-18.  |     | 1         |
| 295 | Hepatitis E Virus. , 0, , 1209-1229.  |     | 1         |
| 296 | Outcomes with Tacrolimus-Based Immunosuppression After Kidney Transplantation from Standard- and Extended-Criteria Donors – A Post Hoc Analysis of the Prospective OSAKA Study. Annals of Transplantation, 2020, 25, e920041. | 0.9 | 1         |
| 297 | Acetate-Free Biofiltration Versus Online Acetate-Free Hemodiafiltration in Patients at High Risk of Hemodialysis Intolerance. Kidney International Reports, 2022, 7, 1108-1111.   | 0.8 | 1         |
| 298 | Hemodynamic and Metabolic Tolerance of Acetate-Free Biofiltration in Mechanically Ventilated Critically Ill Patients: A Real-Life Study. Journal of Clinical Medicine, 2021, 10, 5729.  | 2.4 | 1         |
| 299 | Impact of targeted hypothermia in expanded-criteria organ donors on recipient kidney-graft function: study protocol for a multicentre randomised controlled trial (HYPOREME). BMJ Open, 2022, 12, e052845.                    | 1.9 | 1         |
| 300 | Hepatitis E: The Commonest Viral Zoonosis Worldwide?. , 2015, , 915-935.  |     | 0         |
| 301 | Unusual Pathology in a Kidney from a Heart-Transplant Patient. Case Reports in Transplantation, 2017, 2017, 1-3.  | 0.3 | 0         |
| 302 | Reply to: –Association of hepatitis E virus infection and myasthenia gravis: A pilot study– Journal of Hepatology, 2018, 68, 1321-1322.   | 3.7 | 0         |
| 303 | Hepatitis E Infections in Transplants. , 2021, , 909-925.   |     | 0         |
| 304 | Weekly high-dose liposomal amphotericin B prevents invasive aspergillosis after heart transplantation. Transplant Infectious Disease, 2021, , e13745.   | 1.7 | 0         |
| 305 | Dosing of Enteric-Coated Mycophenolate Sodium Under Routine Conditions: An Observational, Multicenter Study in Kidney Transplantation. Annals of Transplantation, 2016, 21, 250-261.  | 0.9 | 0         |
| 306 | Prevention and Treatment of Viral Hepatitis. , 2019, , 131-144.   |     | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 307 | Effects of intraoperative versus postoperative administration of rabbit antithymocyte antibodies on 1-year renal function in renal transplant patients. <i>Experimental and Clinical Transplantation</i> , 2006, 4, 429-38. | 0.5 | 0         |
| 308 | Impact of mycophenolic acid dose modifications on renal function after kidney transplantation. <i>Experimental and Clinical Transplantation</i> , 2006, 4, 510-7.   | 0.5 | 0         |
| 309 | Renal function and histology in kidney transplant patients receiving tacrolimus and sirolimus or mycophenolate mofetil. <i>Experimental and Clinical Transplantation</i> , 2006, 4, 532-6.                                  | 0.5 | 0         |